Previous close | 4.6800 |
Open | 4.7800 |
Bid | 4.6600 x 100 |
Ask | 4.7400 x 100 |
Day's range | 4.6550 - 4.8100 |
52-week range | 1.8300 - 5.7000 |
Volume | |
Avg. volume | 884,440 |
Market cap | 650.123M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3300 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.79 |
LANGHORNE, Pa., April 08, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA.
AUSTIN, Texas, March 22, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
LANGHORNE, Pa., March 07, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update.